All Articles

The gas and convenience retailer's massive dividend hike follows a stellar quarter, showcasing financial strength in a shifting market.

Facing financial pressures, the biotech divests a key cancer program, repays debt, and now explores all options to maximize value for its remaining pipeline.

The online therapy giant launches a massive giveback, partnering with the WNBA and nonprofits to address the silent mental health crisis facing mothers.

The service commerce platform saw net income jump over 700% despite a drop in adjusted EBITDA, signaling a massive strategic bet on its AI-driven future.

The media giant posted strong Q3 results, driven by a bold strategy to monetize its content with AI partners while aggressively suing content scrapers.

Amidst a 20% workforce cut, Geospace Technologies reports wider losses, testing its high-stakes strategy to pivot from oil & gas to new tech markets.

The environmental services firm posted sequential growth and cut costs, signaling a strategic pivot despite a year-over-year revenue dip.

The institutional crypto exchange is filing for CFTC licenses, a move that could unlock institutional capital and reshape the US digital asset market.

Amid declining Q1 income and NAV, the lender bets on a major healthcare acquisition and a new buyback to bolster shareholder confidence and future growth.

As complex new global AI and data laws take effect, Canadian businesses are scrambling for guidance, fueling a boom in specialized advisory services.

Despite a Q1 net loss, Mach Natural Resources boosts its cash distribution and shifts capital to oil, signaling confidence in its operational strength.

The cloud company's results show modest growth, but a strategic pivot to shed a recent acquisition and focus on its 'Dash' AI tool is paying off.

The AI data protection leader smashed Q1 estimates, raising its full-year outlook as demand for AI governance solutions fuels record revenue and profitability.

With its Q1 earnings call looming, Dollar Tree faces intense scrutiny over its new pricing strategy and what its results signal about consumer health.

Aptar Pharma and the FDA lead a critical mission to reinvent respiratory medicine, ensuring patient safety while tackling the climate impact of inhalers.

The biotech supplier swung to profitability and positive cash flow, driven by a major cost overhaul and strong demand in its core nucleic acid business.

AdCare Rhode Island consolidates services in North Kingstown, creating an integrated care hub to tackle addiction in one of the state's most underserved regions.

The LGBTQ+ app reports record Q1 earnings and plans a premium 'Edge' service, but faces growing challenges with data privacy and anti-gay policies.

The chipmaker topped Q1 estimates and eyes a strong Q2, fueled by EV and AI markets, even as restructuring charges weigh on its bottom line.

With a strong balance sheet and promising data, Enliven Therapeutics is pushing its lead leukemia drug, ELVN-001, into a pivotal late-stage trial.